rs587778193
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_007194.4(CHEK2):c.731A>G(p.Lys244Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000929 in 1,613,930 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_007194.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CHEK2 | NM_007194.4 | c.731A>G | p.Lys244Arg | missense_variant | 6/15 | ENST00000404276.6 | NP_009125.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CHEK2 | ENST00000404276.6 | c.731A>G | p.Lys244Arg | missense_variant | 6/15 | 1 | NM_007194.4 | ENSP00000385747 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152204Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251380Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135870
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461726Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 8AN XY: 727152
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152204Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74336
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 12, 2023 | The p.K244R variant (also known as c.731A>G), located in coding exon 5 of the CHEK2 gene, results from an A to G substitution at nucleotide position 731. The lysine at codon 244 is replaced by arginine, an amino acid with highly similar properties. In one study, this alteration was observed in breast cancer cases as well as healthy controls, and an in vitro assay showed that this alteration had wildtype-like levels of kinase activity (Desrichard A et al. Breast Cancer Res. 2011;13(6):R119). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 16, 2022 | This missense variant replaces lysine with arginine at codon 244 of the CHEK2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). A functional study has shown the mutant protein to exhibit kinase activity similar to the wild-type protein (PMID: 22114986). This variant has been reported in an individual affected with breast cancer (PMID: 22114986) and in two unaffected individuals (PMID: 22114986, 24728327). This variant has been identified in 3/282782 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
CHEK2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 22, 2024 | The CHEK2 c.731A>G variant is predicted to result in the amino acid substitution p.Lys244Arg. This variant has been reported in both cases and controls in a study of women with breast cancer (Desrichard et al. 2011. PubMed ID: 22114986). However, in vitro functional characterization suggested that this variant is not deleterious (Desrichard et al. 2011. PubMed ID: 22114986). This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Aug 03, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer and also in unaffected controls (Desrichard et al., 2011); Published functional studies demonstrate kinase activity similar to wild type (Desrichard et al., 2011); This variant is associated with the following publications: (PMID: 33322746, 22114986, 22419737, 19782031, 24728327, 31050813) - |
Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 02, 2023 | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 244 of the CHEK2 protein (p.Lys244Arg). This variant is present in population databases (rs587778193, gnomAD 0.004%). This missense change has been observed in individual(s) with breast cancer, and an unaffected individual (PMID: 22114986). ClinVar contains an entry for this variant (Variation ID: 133889). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change does not substantially affect CHEK2 function (PMID: 22114986). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Other:1
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at